Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q4 Loss, Beats Revenue Estimates

Crinetics Pharmaceuticals, Inc. (CRNX) came out with a quarterly loss of $1.29 per share versus the Zacks Consensus Estimate of a loss of $1.37. This compares to a loss of $0.88 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +6.01%. A quarter ago, it was expected that this company would post a loss of $1.27 per share when it actually produced a loss of $1.38, delivering a surprise of -8.66%.Over the last four quarters, the co ...